Lokon Pharma

Next generation cancer immunotherapeutics

Our solution

Read more

Clinical trials


Phase I/II study for pancreatic cancer


Read more


Phase I/II study for patients with pancreatic-, biliary-, ovarian-, and colorectal cancer.


Read more


Phase I/II study for patients with malignant melanoma.


Read more


The LOAd family includes a range of novel oncolytic viruses with different immunostimulatory genes that are currently being evaluated for mechanisms-of-action (MOA) and proof-of-concept (POC).

See our pipeline

For patients

If you live in the US and have pancreatic cancer or melanoma, you may be eligible for inclusion in our clinical trials LOKON001 or LOKON003. If you live in Sweden and have pancreatic cancer, melanoma, or ovarian cancer, you may be eligible for inclusion in our clinical trials LOKON002 or LOKON003. If you are interested to participate as a study patient in our trials, please, discuss with your treating physician.

Read more

About Lokon

Lokon Pharma is a Swedish biotech company in the forefront of developing immunostimulatory gene therapy for cancer based on oncolytic viruses. Innovative gene engineering, solid expertise in cancer biology and immunology, as well as a genuine curiosity in life science expand Lokon’s pipeline towards groundbreaking new therapeutics for patients with high unmet medical need.

Read more

Press releases


August 31, 2023
Sara Häggblad, Head of CMC and Titti Björnström, Head of QC/QA from Lokon Pharma will attend the viral vector process development summit on the 30-31th of August. Lokon Pharma will also have a presentation on “Setting out the right criteria for CDMO partners, and how to overcome capacity and availability for viral vector production for speed-to-patient”.
May 19, 2023
Dr Mohamed Hammad, City of Hope, presented our collaboration project using neural stem cells as cell delivery vehicles of Lokon’s LOAd703 at the American Society for Gene and Cell Therapy (ASGCT) in Los Angeles. Stay tuned for the upcoming paper!
October 28, 2022
Jessica Wenthe is presenting her PhD thesis entitled "LOAd703 and beyond - Advancing immunostimulatory gene therapy for cancer" at Rudbeck hall, Rudbeck laboratory, Uppsala University.


Malou efter 10
Bengt fick aggressiv cancer - hade ett år kvar att leva
Immunterapi på 100 sekunder
Malou efter 10
Forskarna om cancervaccinet: ”Behövs pengar”
Uppsala universitet
Immunterapi är ett nytt sätt att bekämpa cancer.